Company intelligence / Profile preview

Telesta Therapeutics Inc.

Montreal, Quebec, Canadaen.wikipedia.org ↗

Ownership: Private
Development stage: Phase 3

Overview

Telesta’s anchor product MCNA completed Phase III trials for non-muscle invasive bladder cancer but failed to secure FDA approval in early 2016. Following this setback and subsequent staff reductions and asset sales, the company was acquired by ProMetic Life Sciences later that year[1][5].

Therapeutic areas: Oncology
Modalities: Biologics (notably MCNA, a biologic therapy)
Industry: Biotech

Drug pipeline

2 assets

PBI-4050

Phase 3

Indications: Idiopathic pulmonary fibrosis, Alström syndrome

1 more asset in the full pipeline.

Request access →

Partnerships

Ipsen licensed rights to MCNA from Telesta prior to acquisition[8].

Beyond the preview

Go deeper on Telesta Therapeutics Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Telesta Therapeutics Inc..

Explore the full profile